# First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

> **NCT01835197** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 79 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-04965842
- **DRUG:** Placebo
- **DRUG:** PF-04965842
- **DRUG:** Placebo
- **DRUG:** PF-04965842
- **DRUG:** Placebo
- **DRUG:** PF-04965842
- **DRUG:** Placebo
- **DRUG:** PF-04965842
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01835197
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2014-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01835197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01835197, "First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01835197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*